Seagen Inc. (SGEN) Financial Analysis & Valuation | Quarter Chart
Seagen Inc. (SGEN)
SGENPrice: $228.74
Fair Value: 🔒
🔒score
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCE... more
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of can... more
Description
Shares
| Market Cap | $43.15B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David R. Epstein |
| IPO Date | 2001-03-09 | CAGR | 0.57% |
| Employees | 3,256 | Website | www.seagen.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.03% | Total Yield | 0.03% |
SGEN chart loading...
Fundamentals
Technicals
| Enterprise Value | $39.60B | P/E Ratio | -57.19 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 21.99 | P/B Ratio | 15.07 |
| P/CF Ratio | -93.1 | P/FCF Ratio | -81.26 |
| EPS | $-4 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 23.4% | Gross Margin | 0.79% |
| Operating Margin | -0.31% | Profit Margin | -0.31% |
| ROE | -0.21% | ROA | -0.17% |
| ROCE | -0.21% | Current Ratio | 2.12 |
| Quick Ratio | 1.6 | Cash Ratio | 0.39 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | 23.26 | Piotroski Score | 2 |